JP Morgan 2019 day two roundup – after the party a harsh reality
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Ash 2018 – Bluebird faces Lentiglobin reckoning
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
Ash 2018 – Global Blood hammers home sickle cell advantage
Investors had been awaiting an update on voxelotor with trepidation, but a lenient FDA has lit up the company’s Ash.
Ash 2018 preview – smaller groups get their turn in the spotlight
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.
Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval
Vertex is due the first pivotal data on its cystic fibrosis triplets, while Global Blood Therapeutics will soon find out whether it can take a shortcut on voxelotor’s…
Most valuable unpartnered assets reveal a changing of the guard
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Global Blood aims for sickle cell dominance
Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.